Literature DB >> 23296936

Natural killer cell reprogramming with chimeric immune receptors.

Noriko Shimasaki1, Dario Campana.   

Abstract

Natural killer (NK) cells are emerging as a new tool for cell therapy of cancer. However, some cancer subtypes are relatively resistant to NK cell cytotoxicity. Expression of anti-CD19 chimeric signaling receptors can enhance NK-cell reactivity against CD19+ leukemia and lymphoma cells. Here we describe a method to enforce expression of such receptors in human NK cells relying on electroporation of mRNA and compare it to retroviral transduction of cDNA. These methods are applicable to the reprogramming of NK cells with chimeric receptors specific for other antigens expressed on cancer cells as well as with molecules that can modulate NK cell function.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23296936     DOI: 10.1007/978-1-62703-260-5_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  9 in total

1.  Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies.

Authors:  Yi Tian Png; Natasha Vinanica; Takahiro Kamiya; Noriko Shimasaki; Elaine Coustan-Smith; Dario Campana
Journal:  Blood Adv       Date:  2017-11-21

2.  Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells.

Authors:  Hua Jiang; Wenhao Zhang; Peipei Shang; Hui Zhang; Weijun Fu; Fei Ye; Tianmei Zeng; Hejing Huang; Xueguang Zhang; Wanping Sun; Daniel Man-Yuen Sze; Qing Yi; Jian Hou
Journal:  Mol Oncol       Date:  2013-12-12       Impact factor: 6.603

3.  A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells.

Authors:  Takahiro Kamiya; Desmond Wong; Yi Tian Png; Dario Campana
Journal:  Blood Adv       Date:  2018-03-13

Review 4.  Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.

Authors:  Dominique Bollino; Tonya J Webb
Journal:  Transl Res       Date:  2017-06-09       Impact factor: 7.012

5.  Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.

Authors:  Chien-Fu Hung; Xuequn Xu; Linhong Li; Ying Ma; Qiu Jin; Angelia Viley; Cornell Allen; Pachai Natarajan; Rama Shivakumar; Madhusudan V Peshwa; Leisha A Emens
Journal:  Hum Gene Ther       Date:  2018-04-02       Impact factor: 5.695

Review 6.  Advantages and applications of CAR-expressing natural killer cells.

Authors:  Wolfgang Glienke; Ruth Esser; Christoph Priesner; Julia D Suerth; Axel Schambach; Winfried S Wels; Manuel Grez; Stephan Kloess; Lubomir Arseniev; Ulrike Koehl
Journal:  Front Pharmacol       Date:  2015-02-12       Impact factor: 5.810

Review 7.  Adoptive T-cell therapy for Leukemia.

Authors:  Haven R Garber; Asma Mirza; Elizabeth A Mittendorf; Gheath Alatrash
Journal:  Mol Cell Ther       Date:  2014-08-12

8.  The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia.

Authors:  R H Rouce; H Shaim; T Sekine; G Weber; B Ballard; S Ku; C Barese; V Murali; M-F Wu; H Liu; E J Shpall; C M Bollard; K R Rabin; K Rezvani
Journal:  Leukemia       Date:  2015-12-01       Impact factor: 11.528

9.  Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing.

Authors:  Tiziano Ingegnere; Francesca Romana Mariotti; Andrea Pelosi; Concetta Quintarelli; Biagio De Angelis; Nicola Tumino; Francesca Besi; Claudia Cantoni; Franco Locatelli; Paola Vacca; Lorenzo Moretta
Journal:  Front Immunol       Date:  2019-04-30       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.